Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof
US-2020165246-A1 · May 28, 2020 · US
Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder
US12486270B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12486270-B2 |
| Application number | US-202217692978-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 11, 2022 |
| Priority date | Sep 13, 2019 |
| Publication date | Dec 2, 2025 |
| Grant date | Dec 2, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Ephrin type receptor tyrosine kinase inhibitors, also known as Eph tyrosine kinase receptor inhibitors, for treating cancer, an inflammatory disease, an autoimmune disease, or a degenerative disease characterized at least in part by the abnormal activity or expression of the Eph receptor tyrosine kinase. The inhibitors are particularly useful for treating certain cancers.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating colorectal cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound selected from or a pharmaceutical composition thereof, wherein the colorectal cancer is characterized by the abnormal activity or expression of the Eph receptor tyrosine kinase. 2 . The method of claim 1 , wherein the cancer is a cancer type in which Eph receptors exert a pro-survival or proliferative function. 3 . The method of claim 1 , further comprising administering an additional therapeutic modality to the subject. 4 . The method of claim 3 , wherein the additional therapeutic modality comprises one or more of chemotherapy, surgery, radiation therapy, immunotherapy, gene therapy, and anti-inflammatory therapy. 5 . A method of treating colorectal cancer in a subject, comprising administering to the subject a therapeutically effective amount of a compound selected from or a pharmaceutical composition comprising the compound, thereby treating the colorectal cancer.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
containing three or more hetero rings · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Three nitrogen atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12486270B2 cover?
- Ephrin type receptor tyrosine kinase inhibitors, also known as Eph tyrosine kinase receptor inhibitors, for treating cancer, an inflammatory disease, an autoimmune disease, or a degenerative disease characterized at least in part by the abnormal activity or expression of the Eph receptor tyrosine kinase. The inhibitors are particularly useful for treating certain cancers.
- Who is the assignee on this patent?
- Us Health, Johann Wolfgang Goethe Univ, Deutsches Krebsforsch
- What technology area does this patent fall under?
- Primary CPC classification C07D473/34. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).